US › Healthcare

Spero Therapeutics Inc (SPRO)

US · Healthcare · Biotechnology

$1.23+6.96%

Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue

$258,000

Revenue YoY

-95.6%

Net profit

$-7.2M

Profit YoY

+48.1%

EPS

$-0.13

Net margin

-2,791.9%

Key statistics

Market cap

$67.7M

P/E

4.3

Forward P/E

0.0

P/B

1.29

Book value

$0.91

EPS (TTM)

$0.27

52-week high

$3.08

52-week low

$1.08

50-day MA

$2.18

200-day MA

$2.36

Beta

1.48

Analyst view

Analysts rate Spero Therapeutics Inc a hold (1 buy, 2 hold, 0 sell out of 3) with an average price target of $4.00.

Shareholding

Insiders

22.46%

Institutions

16.22%

Largest institutional holders

Fund	Stake
GSK PLC	15.87%
Pfizer Inc	4.08%
Vanguard Capital Management, LLC	3.11%
Renaissance Technologies Corp	2.05%
Alphabet Inc	1.54%
Two Sigma Investments LLC	1.53%
Anson Funds Management LP	1.46%
Geode Capital Management, LLC	0.90%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Spero Therapeutics Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Novo Nordisk A/S Amgen Inc Abbott Laboratories Gilead Sciences Inc

Data updated 2026-08-05.